Sunday, September 24, 2023
Clinical Advances in
Read Overview
This educational activity is supported by Pfizer
Rapid Fire
COVID-19: ambulatory antiviral treatment
New Challenge
New Challenge
New Challenge
Steering Committee Chair
Consultant Physician
Regional Infectious Diseases Unit
North Manchester General Hospital
Manchester, United Kingdom
Associate Professor of Infectious Diseases
Department of Biomedical Sciences
Humanitas University, Pieve Emanule (MI), Italy
Head of Infectious Diseases Unit
IRCCS Humanitas Research Hospital
Rozzano (MI), Italy
Professor
Department of Infectious Diseases
Imperial College London
Consultant Physician
Chelsea and Westminster Hospital
London, United Kingdom
Head, Department of Infectious Diseases
University Hospital Ramón y Cajal
Madrid, Spain
Consultant Physician in Internal Medicine and Infectious Diseases
Technical University of Munich
School of Medicine
University Hospital Rechts der Isar
Department of Medicine II
Munich, Germany
Head of Department
Respiratory Medicine and Infectious Disease
University School of Medicine
Hannover, Germany
Steering Committee Chair
Has the following relevant financial relationships:
Consultant or advisor for: Generate; Gilead Sciences, Inc.; GlaxoSmithKline; Merck (Merck Sharp & Dohme); ViiV Healthcare
Speaker or member of speakers bureau for: Gilead Sciences, Inc.; Merck (Merck Sharp & Dohme); ViiV Healthcare
Research funding from: Gilead Sciences, Inc.; Janssen Pharmaceuticals; ViiV Healthcare
Has no relevant financial relationships.
Has the following relevant financial relationships:
Consultant or advisor for: Gilead Sciences, Inc.; GlaxoSmithKline; Merck Sharp & Dohme; Pfizer, Inc.; Roche; ViiV Healthcare
Speaker or member of speakers bureau for: AstraZeneca; Gilead Sciences, Inc.; GlaxoSmithKline; Merck Sharp & Dohme; Pfizer, Inc.; ViiV Healthcare
Research funding from: Gilead Sciences, Inc.; Merck Sharp & Dohme; Moderna; Novavax, Inc.; Valneva; ViiV Healthcare
Has no relevant financial relationships.
Has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; Apeiron; AstraZeneca; Braun Melsungen; BioNtech; Cepheid; Eli Lilly and Company; Formycon; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen-Cilag; Merck Sharp & Dohme; Molecular Partners; Pfizer, Inc.; Roche; Shionogi & Co., Ltd.; SOBI; Synairgen; ViiV Healthcare
Speaker or member of speakers bureau for: AbbVie Inc.; AstraZeneca; BioNtech; Cepheid; Copan; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen-Cilag; Merck Sharp & Dohme; Pfizer, Inc.; Roche; Shionogi & Co., Ltd.; ViiV Healthcare.
Research funding from: Gilead Sciences, Inc.; Janssen Pharmaceuticals; ViiV Healthcare
Contracted researcher for: AbbVie Inc.; Apeiron; Braun Melsungen; Cepheid; Eli Lilly and Company; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen-Cilag; Roche; Merck Sharp & Dohme; Shionogi & Co., Ltd.; ViiV Healthcare.
Has the following relevant financial relationship:
Consultant or advisor for: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Insmed Incorporated; Janssen Pharmaceuticals; Novartis Pharmaceuticals; Pfizer, Inc.; Roche; Sanofi Aventis
Speaker or member of speakers bureau for: AstraZeneca; Biontech; Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Merck Sharp & Dohme; Novartis Pharmaceuticals; Pfizer, Inc.; Roche; Sanofi Aventis